



MAHP Summer Conference

Sunny Hirpara, PharmD

Ross Fortman

Gretchen Glock

Laura Michaels

Our Brands



BYDUREON BCise®
exenatide extended-release
injectable suspension 2 mg

Byetta®
(exenatide) injection

CRESTOR®
rosuvastatin calcium

farxiga®
(dapagliflozin)
5 mg & 10 mg tablets

kombiglyze® XR
(saxagliptin and metformin HCl
extended-release) tablets

LOKELMA®
(sodium zirconium cyclosilicate)
5 g | 10 g for oral suspension

onglyza®
(saxagliptin) 5 mg tablets

Qtern®
(dapagliflozin/saxagliptin)
5 mg/5 mg tablets

SymlinPen®
(pramlintide acetate)
pen-injector

xigduo® XR
(dapagliflozin/metformin HCl
extended-release) tablets

BEVESPI AEROSPHERE®
(glycopyrrolate 9 mcg/formoterol
fumarate 4.8 mcg) Inhalation Aerosol

BREZTRI AEROSPHERE®
(budesonide, glycopyrrolate, and
formoterol fumarate) Inhalation Aerosol

Daliresp®
(roflumilast) tablets

Fasenra®
(benralizumab)
Subcutaneous Injection 30 mg

Fasenra Pen®
(benralizumab)
Subcutaneous Injection 30 mg

Pulmicort Flexhaler®
(budesonide inhalation powder,
90 mcg & 180 mcg)

Pulmicort RESPULSES®
(budesonide inhalation suspension)

Symbicort®
(budesonide/formoterol fumarate
dihydrate) Inhalation Aerosol

CALQUENCE®
(acalabrutinib) 100 mg capsules

FASLODEX®
fulvestrant injection

IMFINZI®
durvalumab
Injection for Intravenous Use 50 mg/mL

IRESSA®
gefitinib

Koselugo®
(selumetinib)
10 mg & 25 mg capsules

Lynparza®
olaparib
tablets 130 mg

TAGRISSO®
osimertinib

FluMist Quadrivalent
Influenza Vaccine Live, Intranasal



Nexium®
lesmesprazole magnesium
For Delayed Release Oral Suspension

Seroquel®
quetiapine

SEROQUEL XR®
quetiapine extended-release
tablets



Estimated Key Regulatory Submission Acceptances 2021 & 2022

	COVID-19 Vaccine AstraZeneca SARS-CoV-2		PT027 asthma
NME	roxadustat# anemia in CKD (H2 2021)†	AZD7442 SARS-CoV-2	<i>Imfinzi</i> + tremelimumab HCC HIMALAYA (Orphan Drug)
	anifrolumab# SLE TULIP 1 & TULIP 2 (Fast Track H2 2021)	tezepelumab# asthma NAVIGATOR (Breakthrough Therapy)	<i>Imfinzi</i> +/- tremelimumab NSCLC POSEIDON
Applications Under Review	H1 2021	H2 2021	2022
LCM	<i>Calquence</i> r/r CLL, high risk ELEVATE-RR	<i>Enhertu</i> DESTINY-Breast03	<i>Enhertu</i> DESTINY-Breast02
	Fasenra nasal polyps OSTRO	<i>Imfinzi</i> + CRT NSCLC PACIFIC-2	<i>Farxiga</i> HF (HFpEF) DELIVER
		<i>Lynparza</i> breast OLYMPIA	<i>Fasenra</i> eosinophilic esophagitis MESSINA (Orphan Drug)
		<i>Lynparza</i> + abiraterone prostate PROPEL	roxadustat# anemia in MDS
		<i>Imfinzi</i> + CTx biliary tract TOPAZ-1 (Orphan Drug)	
		<i>Imfinzi</i> + VEGF + TACE locoregional HCC EMERALD-1	
		<i>Lynparza</i> ovarian SOLO-3	

Partnered and/or in collaboration; † Registrational Phase II/III study; † Delay in regulatory decision due to convening of advisory committee (US).

Note. NME section includes novel combinations and additional indications for assets where the lead is not yet launched